Quest Diagnostics Incorporated Logo

Quest Diagnostics Incorporated

DGX

(2.2)
Stock Price

153,10 USD

17.52% ROA

12.86% ROE

19.66x PER

Market Cap.

16.561.743.260,00 USD

69.23% DER

1.99% Yield

8.82% NPM

Quest Diagnostics Incorporated Stock Analysis

Quest Diagnostics Incorporated Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Quest Diagnostics Incorporated Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 Dividend Growth

The company's dividend growth has exhibited a remarkable upward trend over the past five years, consistently delivering higher returns to investors.

3 ROE

The stock's ROE falls within an average range (12.4%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 PBV

The stock's PBV ratio (2.35x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

5 DER

The stock has a reasonable amount of debt compared to its ownership (76%), suggesting a balanced financial position and a moderate level of risk.

6 Dividend

Investors can take comfort in the fact that the company has consistently distributed dividends over the past three years, demonstrating a commitment to rewarding shareholders.

7 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (1.913) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

Quest Diagnostics Incorporated Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Quest Diagnostics Incorporated Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Quest Diagnostics Incorporated Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Quest Diagnostics Incorporated Revenue
Year Revenue Growth
1996 1.616.296.000
1997 1.528.700.000 -5.73%
1998 1.458.600.000 -4.81%
1999 2.205.200.000 33.86%
2000 3.421.162.000 35.54%
2001 3.627.771.000 5.7%
2002 4.108.051.000 11.69%
2003 4.737.958.000 13.29%
2004 5.126.601.000 7.58%
2005 5.503.711.000 6.85%
2006 6.268.659.000 12.2%
2007 6.704.907.000 6.51%
2008 7.249.400.000 7.51%
2009 7.455.200.000 2.76%
2010 7.368.900.000 -1.17%
2011 7.510.500.000 1.89%
2012 7.382.600.000 -1.73%
2013 7.146.000.000 -3.31%
2014 7.435.000.000 3.89%
2015 7.493.000.000 0.77%
2016 7.515.000.000 0.29%
2017 7.709.000.000 2.52%
2018 7.531.000.000 -2.36%
2019 7.726.000.000 2.52%
2020 9.437.000.000 18.13%
2021 10.788.000.000 12.52%
2022 9.883.000.000 -9.16%
2023 9.180.000.000 -7.66%
2023 9.252.000.000 0.78%
2024 9.588.000.000 3.5%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Quest Diagnostics Incorporated Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Quest Diagnostics Incorporated General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 495.323.000
1997 502.100.000 1.35%
1998 481.600.000 -4.26%
1999 643.400.000 25.15%
2000 1.001.443.000 35.75%
2001 1.018.680.000 1.69%
2002 1.074.841.000 5.23%
2003 1.165.700.000 7.79%
2004 1.227.746.000 5.05%
2005 1.257.775.000 2.39%
2006 1.433.733.000 12.27%
2007 1.612.858.000 11.11%
2008 1.736.934.000 7.14%
2009 1.747.618.000 0.61%
2010 1.707.673.000 -2.34%
2011 1.814.315.000 5.88%
2012 1.745.200.000 -3.96%
2013 1.704.000.000 -2.42%
2014 1.728.000.000 1.39%
2015 1.679.000.000 -2.92%
2016 1.681.000.000 0.12%
2017 1.750.000.000 3.94%
2018 1.424.000.000 -22.89%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Quest Diagnostics Incorporated EBITDA
Year EBITDA Growth
1996 -502.186.000
1997 203.900.000 346.29%
1998 170.100.000 -19.87%
1999 318.800.000 46.64%
2000 455.857.000 30.07%
2001 557.427.000 18.22%
2002 705.365.000 20.97%
2003 946.993.000 25.52%
2004 1.080.227.000 12.33%
2005 1.166.871.000 7.43%
2006 1.333.353.000 12.49%
2007 1.333.255.000 -0.01%
2008 1.540.400.000 13.45%
2009 1.649.100.000 6.59%
2010 1.579.100.000 -4.43%
2011 1.305.100.000 -20.99%
2012 1.519.700.000 14.12%
2013 1.316.000.000 -15.48%
2014 1.327.000.000 0.83%
2015 1.560.000.000 14.94%
2016 1.360.000.000 -14.71%
2017 1.451.000.000 6.27%
2018 1.406.000.000 -3.2%
2019 1.580.000.000 11.01%
2020 2.408.000.000 34.39%
2021 3.158.000.000 23.75%
2022 1.810.000.000 -74.48%
2023 1.800.000.000 -0.56%
2023 1.790.000.000 -0.56%
2024 1.948.000.000 8.11%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Quest Diagnostics Incorporated Gross Profit
Year Gross Profit Growth
1996 605.421.000
1997 653.200.000 7.31%
1998 644.700.000 -1.32%
1999 886.200.000 27.25%
2000 1.453.556.000 39.03%
2001 1.476.177.000 1.53%
2002 1.675.663.000 11.9%
2003 1.969.335.000 14.91%
2004 2.135.889.000 7.8%
2005 2.246.376.000 4.92%
2006 2.572.653.000 12.68%
2007 2.735.059.000 5.94%
2008 2.993.300.000 8.63%
2009 3.133.700.000 4.48%
2010 3.051.700.000 -2.69%
2011 3.115.200.000 2.04%
2012 3.017.900.000 -3.22%
2013 2.820.000.000 -7.02%
2014 2.798.000.000 -0.79%
2015 2.836.000.000 1.34%
2016 2.899.000.000 2.17%
2017 2.990.000.000 3.04%
2018 2.605.000.000 -14.78%
2019 2.689.000.000 3.12%
2020 3.633.000.000 25.98%
2021 4.209.000.000 13.68%
2022 3.433.000.000 -22.6%
2023 3.016.000.000 -13.83%
2023 2.961.000.000 -1.86%
2024 3.104.000.000 4.61%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Quest Diagnostics Incorporated Net Profit
Year Net Profit Growth
1996 -625.960.000
1997 -22.300.000 -2707%
1998 26.900.000 182.9%
1999 -3.400.000 891.18%
2000 102.052.000 103.33%
2001 162.303.000 37.12%
2002 322.154.000 49.62%
2003 436.717.000 26.23%
2004 499.195.000 12.52%
2005 546.277.000 8.62%
2006 586.421.000 6.85%
2007 339.939.000 -72.51%
2008 581.500.000 41.54%
2009 729.100.000 20.24%
2010 720.900.000 -1.14%
2011 470.600.000 -53.19%
2012 555.700.000 15.31%
2013 849.000.000 34.55%
2014 556.000.000 -52.7%
2015 709.000.000 21.58%
2016 645.000.000 -9.92%
2017 772.000.000 16.45%
2018 736.000.000 -4.89%
2019 858.000.000 14.22%
2020 1.431.000.000 40.04%
2021 1.995.000.000 28.27%
2022 946.000.000 -110.89%
2023 900.000.000 -5.11%
2023 854.000.000 -5.39%
2024 916.000.000 6.77%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Quest Diagnostics Incorporated Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 -5
1997 0 0%
1998 0 0%
1999 0 0%
2000 1 0%
2001 1 0%
2002 2 100%
2003 2 50%
2004 2 0%
2005 3 0%
2006 3 0%
2007 2 -100%
2008 3 50%
2009 4 33.33%
2010 4 25%
2011 3 -100%
2012 3 33.33%
2013 6 40%
2014 4 -66.67%
2015 5 25%
2016 5 0%
2017 6 20%
2018 5 0%
2019 6 16.67%
2020 11 40%
2021 16 33.33%
2022 8 -87.5%
2023 8 -14.29%
2023 8 0%
2024 8 12.5%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Quest Diagnostics Incorporated Free Cashflow
Year Free Cashflow Growth
1996 -158.882.000
1997 129.500.000 222.69%
1998 100.900.000 -28.34%
1999 -851.500.000 111.85%
2000 253.005.000 436.55%
2001 316.817.000 20.14%
2002 441.175.000 28.19%
2003 488.158.000 9.62%
2004 622.655.000 21.6%
2005 627.313.000 0.74%
2006 758.474.000 17.29%
2007 707.823.000 -7.16%
2008 850.400.000 16.77%
2009 830.500.000 -2.4%
2010 912.600.000 9%
2011 734.000.000 -24.33%
2012 1.004.900.000 26.96%
2013 421.000.000 -138.69%
2014 630.000.000 33.17%
2015 547.000.000 -15.17%
2016 776.000.000 29.51%
2017 923.000.000 15.93%
2018 817.000.000 -12.97%
2019 843.000.000 3.08%
2020 1.587.000.000 46.88%
2021 1.830.000.000 13.28%
2022 1.314.000.000 -39.27%
2023 102.000.000 -1188.24%
2023 864.000.000 88.19%
2024 268.000.000 -222.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Quest Diagnostics Incorporated Operating Cashflow
Year Operating Cashflow Growth
1996 -88.486.000
1997 176.300.000 150.19%
1998 141.400.000 -24.68%
1999 249.500.000 43.33%
2000 369.455.000 32.47%
2001 465.803.000 20.68%
2002 596.371.000 21.89%
2003 662.799.000 10.02%
2004 798.780.000 17.02%
2005 851.583.000 6.2%
2006 951.896.000 10.54%
2007 926.924.000 -2.69%
2008 1.063.100.000 12.81%
2009 997.400.000 -6.59%
2010 1.118.000.000 10.79%
2011 895.500.000 -24.85%
2012 1.187.100.000 24.56%
2013 652.000.000 -82.07%
2014 938.000.000 30.49%
2015 810.000.000 -15.8%
2016 1.069.000.000 24.23%
2017 1.175.000.000 9.02%
2018 1.200.000.000 2.08%
2019 1.243.000.000 3.46%
2020 2.005.000.000 38%
2021 2.233.000.000 10.21%
2022 1.718.000.000 -29.98%
2023 207.000.000 -729.95%
2023 1.272.000.000 83.73%
2024 360.000.000 -253.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Quest Diagnostics Incorporated Capital Expenditure
Year Capital Expenditure Growth
1996 70.396.000
1997 46.800.000 -50.42%
1998 40.500.000 -15.56%
1999 1.101.000.000 96.32%
2000 116.450.000 -845.47%
2001 148.986.000 21.84%
2002 155.196.000 4%
2003 174.641.000 11.13%
2004 176.125.000 0.84%
2005 224.270.000 21.47%
2006 193.422.000 -15.95%
2007 219.101.000 11.72%
2008 212.700.000 -3.01%
2009 166.900.000 -27.44%
2010 205.400.000 18.74%
2011 161.500.000 -27.18%
2012 182.200.000 11.36%
2013 231.000.000 21.13%
2014 308.000.000 25%
2015 263.000.000 -17.11%
2016 293.000.000 10.24%
2017 252.000.000 -16.27%
2018 383.000.000 34.2%
2019 400.000.000 4.25%
2020 418.000.000 4.31%
2021 403.000.000 -3.72%
2022 404.000.000 0.25%
2023 105.000.000 -284.76%
2023 408.000.000 74.26%
2024 92.000.000 -343.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Quest Diagnostics Incorporated Equity
Year Equity Growth
1996 538.719.000
1997 541.700.000 0.55%
1998 567.900.000 4.61%
1999 863.100.000 34.2%
2000 1.031.795.000 16.35%
2001 1.335.987.000 22.77%
2002 1.768.863.000 24.47%
2003 2.394.694.000 26.13%
2004 2.288.651.000 -4.63%
2005 2.762.984.000 17.17%
2006 3.019.171.000 8.49%
2007 3.324.242.000 9.18%
2008 3.604.900.000 7.79%
2009 4.011.400.000 10.13%
2010 4.054.000.000 1.05%
2011 3.715.000.000 -9.13%
2012 4.185.800.000 11.25%
2013 3.973.000.000 -5.36%
2014 4.330.000.000 8.24%
2015 4.783.000.000 9.47%
2016 4.737.000.000 -0.97%
2017 5.035.000.000 5.92%
2018 5.344.000.000 5.78%
2019 5.763.000.000 7.27%
2020 6.891.000.000 16.37%
2021 6.562.000.000 -5.01%
2022 6.007.000.000 -9.24%
2023 6.418.000.000 6.4%
2023 6.539.000.000 1.85%
2024 6.735.000.000 2.91%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Quest Diagnostics Incorporated Assets
Year Assets Growth
1996 1.395.066.000
1997 1.400.900.000 0.42%
1998 1.360.200.000 -2.99%
1999 2.878.500.000 52.75%
2000 2.864.536.000 -0.49%
2001 2.930.555.000 2.25%
2002 3.324.197.000 11.84%
2003 4.301.418.000 22.72%
2004 4.203.788.000 -2.32%
2005 5.306.115.000 20.77%
2006 5.661.482.000 6.28%
2007 8.565.693.000 33.91%
2008 8.403.800.000 -1.93%
2009 8.563.600.000 1.87%
2010 8.527.600.000 -0.42%
2011 9.313.400.000 8.44%
2012 9.283.900.000 -0.32%
2013 8.948.000.000 -3.75%
2014 9.877.000.000 9.41%
2015 9.962.000.000 0.85%
2016 10.100.000.000 1.37%
2017 10.503.000.000 3.84%
2018 11.003.000.000 4.54%
2019 12.843.000.000 14.33%
2020 14.026.000.000 8.43%
2021 13.611.000.000 -3.05%
2022 12.837.000.000 -6.03%
2023 14.022.000.000 8.45%
2023 13.482.000.000 -4.01%
2024 13.881.000.000 2.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Quest Diagnostics Incorporated Liabilities
Year Liabilities Growth
1996 856.347.000
1997 859.200.000 0.33%
1998 792.300.000 -8.44%
1999 2.015.400.000 60.69%
2000 1.832.741.000 -9.97%
2001 1.594.568.000 -14.94%
2002 1.555.334.000 -2.52%
2003 1.906.724.000 18.43%
2004 1.915.137.000 0.44%
2005 2.543.131.000 24.69%
2006 2.642.311.000 3.75%
2007 5.241.451.000 49.59%
2008 4.798.900.000 -9.22%
2009 4.552.200.000 -5.42%
2010 4.473.600.000 -1.76%
2011 5.598.400.000 20.09%
2012 5.098.100.000 -9.81%
2013 4.975.000.000 -2.47%
2014 5.547.000.000 10.31%
2015 5.179.000.000 -7.11%
2016 5.363.000.000 3.43%
2017 5.468.000.000 1.92%
2018 5.659.000.000 3.38%
2019 7.080.000.000 20.07%
2020 7.135.000.000 0.77%
2021 7.049.000.000 -1.22%
2022 6.830.000.000 -3.21%
2023 7.604.000.000 10.18%
2023 6.943.000.000 -9.52%
2024 7.146.000.000 2.84%

Quest Diagnostics Incorporated Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
84.2
Net Income per Share
7.57
Price to Earning Ratio
19.66x
Price To Sales Ratio
1.77x
POCF Ratio
13.23
PFCF Ratio
18.93
Price to Book Ratio
2.5
EV to Sales
2.29
EV Over EBITDA
11.93
EV to Operating CashFlow
17.13
EV to FreeCashFlow
24.43
Earnings Yield
0.05
FreeCashFlow Yield
0.05
Market Cap
16,56 Bil.
Enterprise Value
21,38 Bil.
Graham Number
100.75
Graham NetNet
-52.2

Income Statement Metrics

Net Income per Share
7.57
Income Quality
1.47
ROE
0.13
Return On Assets
0.05
Return On Capital Employed
0.09
Net Income per EBT
0.76
EBT Per Ebit
0.84
Ebit per Revenue
0.14
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.32
Operating Profit Margin
0.14
Pretax Profit Margin
0.12
Net Profit Margin
0.09

Dividends

Dividend Yield
0.02
Dividend Yield %
1.99
Payout Ratio
0.38
Dividend Per Share
2.96

Operating Metrics

Operating Cashflow per Share
11.24
Free CashFlow per Share
7.88
Capex to Operating CashFlow
0.3
Capex to Revenue
0.04
Capex to Depreciation
0.82
Return on Invested Capital
0.09
Return on Tangible Assets
0.18
Days Sales Outstanding
51.51
Days Payables Outstanding
71.08
Days of Inventory on Hand
10.51
Receivables Turnover
7.09
Payables Turnover
5.13
Inventory Turnover
34.73
Capex per Share
3.36

Balance Sheet

Cash per Share
2,44
Book Value per Share
60,68
Tangible Book Value per Share
-21.19
Shareholders Equity per Share
59.61
Interest Debt per Share
42.86
Debt to Equity
0.69
Debt to Assets
0.33
Net Debt to EBITDA
2.69
Current Ratio
1
Tangible Asset Value
-2,35 Bil.
Net Current Asset Value
-5,13 Bil.
Invested Capital
11527000000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.65
Average Receivables
1,32 Bil.
Average Payables
1,23 Bil.
Average Inventory
181500000
Debt to Market Cap
0.28

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Quest Diagnostics Incorporated Dividends
Year Dividends Growth
2004 1
2005 1 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1 0%
2013 1 100%
2014 1 0%
2015 1 0%
2016 2 0%
2017 2 0%
2018 2 0%
2019 2 50%
2020 2 0%
2021 2 0%
2022 3 0%
2023 3 0%
2024 3 0%

Quest Diagnostics Incorporated Profile

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

CEO
Mr. James E. Davis
Employee
50.000
Address
500 Plaza Drive
Secaucus, 07094

Quest Diagnostics Incorporated Executives & BODs

Quest Diagnostics Incorporated Executives & BODs
# Name Age
1 Mr. Michael E. Prevoznik J.D.
Senior Vice President & General Counsel
70
2 Ms. Catherine T. Doherty
Executive Vice President of Regional Businesses
70
3 Mr. Murali Balakumar
Senior Vice President, Chief Information & Digital Officer
70
4 Mr. Gary D. Samuels
Senior Vice President & Chief Communications Officer
70
5 Mr. James E. Davis
Chairman, Chief Executive Officer & President
70
6 Mr. Karthik Kuppusamy Ph.D.
Senior Vice President of Clinical Solutions
70
7 Mr. Michael J. Deppe
Senior Vice President, Corporate Controller & Chief Accounting Officer
70
8 Mr. Shawn C. Bevec
Vice President of Investor Relations
70
9 Ms. Kristin Lee Wallace Esq.
Senior Vice President & Chief Compliance Officer
70
10 Mr. Sam A. Samad
Executive Vice President & Chief Financial Officer
70

Quest Diagnostics Incorporated Competitors